Previous 10 | Next 10 |
2023-12-27 09:21:21 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena announces private placement and warrant exercise
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“ Trevena ” or the “ Company ”) ( Nasdaq: TRVN ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CN...
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P 1 receptor without associated lymphopenia ...
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OL...
2023-12-01 17:23:01 ET More on Trevena Trevena Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena files for $200M ...
CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the p...
2023-11-14 09:21:04 ET Trevena, Inc. (TRVN) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Barry Shin - Senior Vice President, Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Seni...
2023-11-14 07:05:06 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena GAAP EPS of -$0.57 misses by $0.42, revenue of $0.18M beats by $0...
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK ...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- ...